Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injection

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative treatment of advanced prostatic cancer.

The approval by the US Food and Drug Administration (USFDA) is for Leuprolide Acetate injection of strengths 14 mg/2.8 ml (1 mg/0.2 mL) multiple-dose vial (reference listed drug Lupron Injection, 1 mg/0.2 mL), Zydus Lifesciences said in a regulatory filing.

The Leuprolide Acetate injections will be manufactured at the company’s oncology injectable manufacturing facility at SEZ1, Ahmedabad, it added.

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. It had annual sales of USD 69 million in the US, the company said citing IQVIA MAT September 2025 data.

Related Posts

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

Prices of nearly 900 essential medicines, including painkillers and antibiotics, are set to rise by around 0.65 per cent starting 1 April following a directive from India’s drug pricing regulator.…

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

The court also asked Dr Reddy’s to inform it by Friday whether it is willing to drop the “Olymviq” brand name, as the matter centres around alleged trademark similarity with…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

24-year-old woman dies during surgery; Five UP doctors booked for negligence

24-year-old woman dies during surgery; Five UP doctors booked for negligence